Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 152 publications
ASK1/ p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
Journal: Hepatology (Baltimore, Md.)
Published: June 16, 2023
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Journal: The lancet. Gastroenterology & hepatology
Published: January 19, 2021
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Journal: Hepatology (Baltimore, Md.)
Published: November 29, 2018
Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes.
Journal: eLife
Published: October 03, 2018
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: July 12, 2018
Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
Journal: Journal of hepatology
Published: April 24, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
Journal: Hepatology (Baltimore, Md.)
Published: March 14, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Journal: Gastroenterology
Published: March 12, 2018
Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.
Journal: The Journal of infectious diseases
Published: February 14, 2018
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: February 02, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Journal: The lancet. Gastroenterology & hepatology
Published: January 31, 2018
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Journal: Hepatology international
Published: January 30, 2018
Last Updated: 09/26/2026